: Secondary sphere formation timeline for JLK1486 and TMZ+JLK1486 dosing, dissociation, and counting of non-adherent and primary lines. (A) Scheme of secondary sphere formation assay depicting timeline of when U87NS and U118NS cell lines were treated with JLK1486 alone, counted, dissociated, and re-counted. (B) Scheme of secondary sphere formation assay depicting timeline of when GS8-26 and 5075 primary cell lines were treated with JLK1486 alone, counted, dissociated, and re-counted. (C) Scheme of secondary sphere formation assay depicting timeline of when U87NS and U118NS cell lines were treated with both JLK1486 and TMZ. GS8-26 and 5075 primary lines followed scheme shown in panel (B). D. Scheme of secondary sphere formation assay depicting timeline of when U87NS and U118NS cell lines were treated once (1X) with TMZ and twice (2X) with JLK1486. GS8-26 and 5075 primary lines followed scheme shown in panel (B).
